Mindy J. Allport-Settle has over 25 years of experience in health care and in the pharmaceutical, medical device, and biotechnology industry with a focus on translational medicine. This is a view of medical practice and interventional epidemiology as a natural progression from evidence-based medicine. It integrates research inputs from the basic sciences, social sciences and political sciences to optimize both patient care and preventive measures which may extend beyond the provision of common healthcare services. This focus on turning biological discoveries into drugs and medical devices underpinned with applied medical research and rapid clinical trials (i.e. traditional medicine and pharmaceuticals, dietary supplements, and homeopathies combined with chiropractic and other physiological support modalities) supports digital modeling and the use of broader technology to enhance product pipelines. Chief among these successes is her work with HER2/neu and H1N1 vaccine development and novel combined devices for insulin delivery as well as innovating regulatory agency interactions toward a more streamlined and agile delivery to patients.
Her career began as a professional musician with her first public stage performance at thirteen years old in Charleston, West Virginia. Later, she chose to complete her high school education at North Carolina School of the Arts. While in arts school she was exposed to diverse forms of art and came to understand the importance of the human body as an artistic instrument. This piqued her early interest in health care and as a teenager she began working as an emergency medical technician. Later, she joined the U.S. Navy's advanced hospital corps and then attended Wake Forest University's Bowman Gray School of Medicine (specializing in ophthalmology and organ and human tissue procurement). Her educational background includes a Bachelor’s degree from the University of North Carolina and an MBA in Global Management from the University of Phoenix and completion of the corporate governance course series in audit and compensation committees and board effectiveness at Harvard Business School.
Professionally, she has served as a key executive, board member, and consultant for some of the best companies in the pharmaceutical, medical device, and biotechnology industry. At the age of 32, she was the youngest elected member of the Board of Directors of a publicly traded company in North America (Generex Biotechnology, NASDAQ: GNBT) where she served as the Chairman of the Compensation Committee and a member of the Audit and Regulatory Compliance Committees. She also proudly served as a Senate and Congressional lobbyist in the United States for government healthcare reform and the inclusion and promotion of novel therapies in Washington, DC and as a representative of patient protection and commercial integration strategies internationally. She developed the only FDA-recognized and benchmarked quality systems training and development business methodology and has authored more than 30 industry-leading books balancing regulatory requirements, shareholder expectations, patient protection, and community outreach.
Today, Ms. Allport-Settle continues to provide expert guidance in regulatory compliance (both domestic and international law), corporate structuring, restructuring and turnarounds, new drug submissions, research and development, product commercialization, and new business development.
Her career began as a professional musician with her first public stage performance at thirteen years old in Charleston, West Virginia. Later, she chose to complete her high school education at North Carolina School of the Arts. While in arts school she was exposed to diverse forms of art and came to understand the importance of the human body as an artistic instrument. This piqued her early interest in health care and as a teenager she began working as an emergency medical technician. Later, she joined the U.S. Navy's advanced hospital corps and then attended Wake Forest University's Bowman Gray School of Medicine (specializing in ophthalmology and organ and human tissue procurement). Her educational background includes a Bachelor’s degree from the University of North Carolina and an MBA in Global Management from the University of Phoenix and completion of the corporate governance course series in audit and compensation committees and board effectiveness at Harvard Business School.
Professionally, she has served as a key executive, board member, and consultant for some of the best companies in the pharmaceutical, medical device, and biotechnology industry. At the age of 32, she was the youngest elected member of the Board of Directors of a publicly traded company in North America (Generex Biotechnology, NASDAQ: GNBT) where she served as the Chairman of the Compensation Committee and a member of the Audit and Regulatory Compliance Committees. She also proudly served as a Senate and Congressional lobbyist in the United States for government healthcare reform and the inclusion and promotion of novel therapies in Washington, DC and as a representative of patient protection and commercial integration strategies internationally. She developed the only FDA-recognized and benchmarked quality systems training and development business methodology and has authored more than 30 industry-leading books balancing regulatory requirements, shareholder expectations, patient protection, and community outreach.
Today, Ms. Allport-Settle continues to provide expert guidance in regulatory compliance (both domestic and international law), corporate structuring, restructuring and turnarounds, new drug submissions, research and development, product commercialization, and new business development.